[an error occurred while processing this directive] | [an error occurred while processing this directive]
Predictive factors for radiation-induced lung injury in locally advanced non-small cell lung cancer after intensity-modulated radiotherapy
Sun Shuai, Chen Xinyuan, Wang Jingbo, Ji Zhe, Bi Nan, Zhou Zongmei, Feng Qinfu, Hui Zhouguang, Liang Jun, Xiao Zefen, Lyu Jima, Wang Xiaozhen, Yin Weibo, Wang Lyuhua
Department of Radiation Oncology, Cancer Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100021, China
Abstract Objective To investigate the incidence of radiation-induced lung injury (RILI) in patients with locally advanced non-small cell lung cancer (LA-NSCLC) after involved-field intensity-modulated radiotherapy (IMRT) and concurrent chemotherapy, and to figure out the predictive factors for RILI. Methods Two hundred and fifty-six patients with stage Ⅲ NSCLC who were treated without surgery in our hospital from January 2007 to December 2011 were enrolled as subjects. All patients received involved-field IMRT with a median dose of 60 Gy (50-70 Gy) in 30 fractions. In all patients, 109 patients (42.6%) received concurrent chemotherapy. The National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 was used to evaluate the RILI grade. The incidence of grade ≥2 RILI (symptomatic RILI, SRILI) within 6 months after radiotherapy served as the end point. The predictive factors for RILI were analyzed using logistic regression model. Results In all patients, 215(84%) were male, and 41(16%) were female. The mean age at diagnosis was 59.2 years. Forty-three (16.7%) patients had grade ≥2 RILI. The mean duration between the incidence of RILI and the beginning of radiotherapy was 64 days (20-169 days). Univariate analysis showed that smoking, peripheral or central tumor location, mean lung dose (MLD) for both lungs, and V5-V20 for both lungs were suspected to be associated with the development of SRILI (P=0.108,0.106,0.030,0.049). Multivariate analysis showed the MLD and V5-V20 for both lungs were independent predictive factors for SRILI P=(0.048). Conclusions For patients with LA-NSCLC treated with involved-field IMRT, the MLD and the volume of low-dose region in dose volume histogram for both lungs are significantly correlated with the incidence of SRILI.
Sun Shuai,Chen Xinyuan,Wang Jingbo et al. Predictive factors for radiation-induced lung injury in locally advanced non-small cell lung cancer after intensity-modulated radiotherapy[J]. Chinese Journal of Radiation Oncology, 2015, 24(5): 479-483.
Sun Shuai,Chen Xinyuan,Wang Jingbo et al. Predictive factors for radiation-induced lung injury in locally advanced non-small cell lung cancer after intensity-modulated radiotherapy[J]. Chinese Journal of Radiation Oncology, 2015, 24(5): 479-483.
[1] Rosenzweig KE,Fox JL,Yorke E,et al. Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable non-small-cell lung carcinoma[J].Cancer,2005,103(10):2118-2127.DOI:10.1002/cncr.21007. [2] Rodrigues G,Lock M,D′Souza D,et al. Prediction of radiation pneumonitis by dose-volume histogram parameters in lung cancer-a systematic review[J].Radiother Oncol,2004,71(2):127-138.DOI:10.1016/j.radonc.2004.02.015. [3] Kong FM,Ten Haken R,Eisbruch A,et al. Non-small cell lung cancer therapy-related pulmonary toxicity:an update on radiation pneumonitis and fibrosis[J].Semin Oncol,2005,32(Suppl 3):42-54.DOI:10.1053/j.seminoncol.2005.03.009. [4] Kong FM,Hayman JA,Griffith KA,et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC):predictors for radiation pneumonitis and fibrosis[J].Int J Radiat Oncol Biol Phys,2006,65(4):1075-1086.DOI:10.1016/j.ijrobp.2006.01.051. [5] 朱向帜,王绿化,王颖杰,等.三维适形放疗局部晚期非小细胞肺癌的放射性肺炎风险因素研究[J].中华放射肿瘤学杂志,2007,16(6):421-426.DOI:10.3760/j.issn:1004-4221.2007.06.004. [6] 王澜,李晓宁,吕冬婕,等.肺低剂量区体积预测急性放射性肺炎价值探讨[J].中华放射肿瘤学杂志,2010,19(4):296-300.DOI:10.3760/cma.j.issn.1004-4221.2010.04.005. [7] 王静波,曹建忠,姬巍,等.局部晚期非小细胞肺癌三维放疗后放射性肺损伤风险因素分析[J].中华放射肿瘤学杂志,2012,21(2):114-120.DOI:10.3760/cma.j.issn.1004-4221.2012.02.006. [8] Robnett TJ,Machtay M,Vines EF,et al. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer[J].Int J Radiat Oncol Biol Phys,2000,48(1):89-94.DOI:10.1016/S0360-3016(00)00648- 9. [9] Dehing-Oberije C,De Ruysscher D,Van Baardwijk A,et al. The importance of patient characteristics for the prediction of radiation-induced lung toxicity[J].Radiother Oncol,2009,91(3):421-426.DOI:10.1016/j.radonc.2008.12.002. [10] Wang JB,Cao JZ,Yuan SH,et al. Poor baseline pulmonary function may not increase the risk of radiation-induced lung toxicity[J].Int J Radiat Oncol Biol Phys,2013,85(3):798-804.DOI:10.1016/j.ijrobp.2012.06.040. [11] Hernando ML,Marks LB,Bentel GC,et al. Radiation-induced pulmonary toxicity:a dose-volume histogram analysis in 201 patients with lung cancer[J].Int J Radiat Oncol Biol Phys,2001,51(3):650-659.DOI:10.1016/S0360-3016(01)01685-6. [12] Hope AJ,Lindsay PE,El Naqa I,et al. Modeling radiation pneumonitis risk with clinical,dosimetric,and spatial parameters[J].Int J Radiat Oncol Biol Phys,2006,65(1):112-124.DOI:10.1016/j.ijrobp.2005.11.046. [13] Rancati T,Ceresoli GL,Gagliardi G,et al. Factors predicting radiation pneumonitis in lung cancer patients:a retrospective study[J].Radiother Oncol,2003,67(3):275-283.DOI:10.1016/S0167-8140(03)00119-1. [14] Marks LB,Bentzen SM,Deasy JO,et al. Radiation dose-volume effects in the lung[J].Int J Radiat Oncol Biol Phys,2010,76(3 Suppl):S70-76.DOI:10.1016/j.ijrobp.2009.06.091. [15] Palma DA,Senan S,Tsujino K,et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer:an international individual patient data meta-analysis[J].Int J Radiat Oncol Biol Phys,2013,85(2):444-450.DOI:10.1016/j.ijrobp.2012.04.043. [16] Wang LH,Wu SX,Ou GF,et al. Randomized phase Ⅱ study of concurrent cisplatin/etoposide or paclitaxel/carboplatin and thoracic radiotherapy in patients with stage Ⅲ non-small cell lung cancer[J].Lung Cancer,2012,77(1):89-96.DOI:10.1016/j.lungcan.2012.02.011. [17] Perrier L,Buja A,Mastrangelo G,et al. Transferability of health cost evaluation across locations in oncology:cluster and principal component analysis as an explorative tool[J].BMC Health Serv Res,2014,14:537.DOI:10.1186/s12913-014-0537-x. [18] Guo JJ,Jing YH,Nguyen K,et al. Principal components analysis of drug expenditure and utilisation trends for major therapeutic classes in US Medicaid programmes[J].J Med Econ,2008,11(4):671-694.DOI:10.3111/13696990802579966. [19] Holmes GM,Pink GH.Adoption and perceived effectiveness of financial improvement strategies in critical access hospitals[J].J Rural Health,2012,28(1):92-100.DOI:10.1111/j.1748-0361.2011.00368.x. [20] Ding C,He XF.K-means clustering via principal component analysis[A]//Proceeding ICML’04:proceedings of the 21th international conference on machine learning[C].New York:ACM,2004.DOI:10.1145/1015330.1015408. [21] Dang J,Li G,Ma LH,et al. Predictors of grade ≥ 2 and grade ≥ 3 radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with three-dimensional conformal radiotherapy[J].Acta Oncol,2013,52(6):1175-1180.DOI:10.3109/0284186X.2012.747696. [22] Song CH,Pyo H,Moon SH,et al. Treatment-related pneumonitis and acute esophagitis in non-small-cell lung cancer patients treated with chemotherapy and helical tomotherapy[J].Int J Radiat Oncol Biol Phys,2010,78(3):651-658.DOI:10.1016/j.ijrobp.2009.08.068.
2015, Vol. 24 
